Live Breaking News & Updates on A Larger Phase 3 Clinical Study Is Needed To Confirm These Results From The 2 Trial Are Published In Infectious Diseases And Therapy Were Presented At Scientific Sessions Of Ats 2022 International Conference San Francisco

In hospitalized patients with COVID-19 Pneumonia, the rates of clinical events among those treated with Reparixin (n=36) were statistically significantly lower than standard of care (n=19). The study is the first evaluation of the efficacy and safety of Reparixin an IL-8 inhibitor in patients with severe COVID-19 pneumonia. Results from the Phase 2 trial were presented at the American Thoracic Society (ATS) 2022 International Conference and published in Infectious Diseases and Therapy MILAN, June 13, 2022 /PRNewswire/ Dompe farmaceutici S.p.A ("Dompe") today announcedresults from its Phase 2 clinical trial demonstrating that, in patients in severe COVID-19 Pneumonia, Reparixin led to an improvement in clinical outcomes when compared with the standard of care, a larger phase 3 clinical study is needed to confirm these results. Results from the Phase 2 trial are published in Infectious Diseases and Therapy and were presented at the scientific sessions of the ATS 2022 Internati ....

San Francisco Bay , United States , San Francisco , Flavio Mantelli , Giovanni Landoni , Dompe Farmaceutici , International Conference , American Thoracic Society , Infectious Diseases , Intensive Care , Hospital San Raffaele , Chief Medical Officer , San Francisco Bay Area , In Hospitalized Patients With Covid 19 Pneumonia , He Rates Of Clinical Events Among Those Treated With Reparixinn 36 Were Statistically Significantly Lower Than Standard Caren 19 The Study Is First Evaluation Efficacy And Safety Reparixin An Il 8 Inhibitor In Patients Severe Covid Pneumonia Results From Phase 2 Trial Presented At American Thoracic Society Ats 2022 International Conference Published Infectious Diseases Therapy Milan , June 13 , 022 Prnewswire Dompe Farmaceuticis Pa Quot Today Announcedresults From Its Phase 2 Clinical Trial Demonstrating That , N Patients In Severe Covid 19 Pneumonia , Eparixin Led To An Improvement In Clinical Outcomes When Compared With The Standard Of Care , A Larger Phase 3 Clinical Study Is Needed To Confirm These Results From The 2 Trial Are Published In Infectious Diseases And Therapy Were Presented At Scientific Sessions Of Ats 2022 International Conference San Francisco , Alifornia Acute Lung Injury And Respiratory Distress Syndrome Ards Are Common Complications In Patients With Covid 19 1 As Part Of Its Commitment To Invest Research For Unmet Medical Needs , Ompe Conducted An Open Label , Ulti Center Study To Evaluate The Inhibition Of Il 8 Which Is Known Be Associated With Cytokine Release Syndrome Connected Covid 19 Disease Quot Reparixin Isa New Investigational Molecule That Seems Havea Novel Application In Patients Acute Respiratory Inflammation Induced By It Was Well Tolerated Clinical Studies , Uot Said Giovanni Landoni , Irector Of Care Center For Intensive And Anesthesiology At Hospital San Raffaele In Milan , Taly Quot The Outcomes As Compared To Standard Of Care May Now Be Reduced By Widespread Use Covid 19 Vaccines ,